Every 424B that EVOMMUNE INC (EVMN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow EVMN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full EVMN filings page.
Evommune, Inc. reports substantially higher operating spend and losses as it advances multiple inflammatory-disease programs. For the quarter ended June 30, 2026, it generated no revenue and recorded a net loss of $32.2 million, or $0.89 per share, driven by research and development expenses of $26.4 million and general and administrative expenses of $8.5 million.
For the first half of 2026, the net loss was $53.9 million. In June 2026, a Phase 2b trial of EVO756 in chronic spontaneous urticaria failed to meet its primary endpoint, and Evommune will cease that indication, while continuing Phase 2b studies in atopic dermatitis and migraine. A February 2026 private placement raised $117.2 million, contributing to $288.0 million in cash, cash equivalents and investments at June 30, 2026, which management expects will fund operations under the current plan through 2028.
Evommune, Inc. furnished a Form 8-K and prospectus supplement reporting top-line results from the randomized, double-blind, placebo-controlled Phase 2b trial of oral MRGPRX2 antagonist EVO756 in adults with moderate-to-severe chronic spontaneous urticaria (CSU). The trial enrolled 160 antihistamine-refractory CSU patients across the United States, Europe, Canada and Japan and tested three active dose regimens versus placebo.
The study did not meet its primary endpoint of mean change in Urticaria Activity Score over seven days (UAS7) at 12 weeks at any dose. Based on these results, the company plans to cease development of EVO756 for CSU while continuing to evaluate the compound in other indications. The press release was issued and furnished as Exhibit 99.1 on June 29, 2026.
Evommune, Inc. held its 2026 Annual Meeting of Stockholders and announced director election results and auditor ratification. Luís Peña and Eugene Bauer, M.D. were elected to the Board with reported votes of 21,859,596 and 23,637,920 respectively. The selection of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified by a vote of 24,664,299 in favor.
The prospectus supplement updates the S-1 prospectus dated April 24, 2026 and incorporates the Company’s Form 8-K filed June 2, 2026; the supplement refers readers to the Prospectus for risk disclosures. The supplement states the last reported sale price of common stock was $22.17 per share on June 1, 2026.
Evommune, Inc. filed a prospectus supplement to its S-1 that incorporates its Form 10-Q for the quarter ended March 31, 2026 and updates the offering materials.
The supplement discloses cash, cash equivalents and investments of approximately $307.0 million, a net loss of $21.7 million ($0.64 per share) for Q1 2026, and 36,018,372 shares outstanding as of May 5, 2026. The Company raised net proceeds of $117.2 million in February 2026 from a private placement of 4,494,279 shares at $27.88 per share and states existing resources are expected to fund operations through 2028 under its current plan.
The supplement reiterates clinical development plans: EVO756 Phase 2b CSU initial results expected June 2026, EVO756 AD initial results expected Q3 2026, planned EVO756 migraine Phase 2b start mid-2026, and EVO301 Phase 2b planned to commence mid-2027.
Evommune, Inc. registers 4,494,279 shares of common stock for resale by selling stockholders.
The prospectus covers the resale from time to time of up to 4,494,279 Shares by the selling stockholders; the company will not receive proceeds from these resales. Shares outstanding were 36,018,372 as of March 31, 2026.